Overview

To Evaluate Safety and Efficacy of Autologous CD19 Chimeric Antigen Receptor (CAR)-T Cells in Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL)

Status:
RECRUITING

Trial end date:
2026-06-02

Target enrollment:

Participant gender:

Summary

A Phase II Open-Label Single-arm Study to Evaluate Safety and Efficacy of locally manufactured autologous CD19-directed CAR T-cells in Patients with Relapsed/Refractory B- Non-Hodgkin Lymphoma (B-NHL) or patients not eligible for hematopoietic stem cell transplantation (HCT)

Phase:

PHASE2

Details

Lead Sponsor:

National University of Malaysia

Collaborator:

Plutonet Sdn Bhd

Treatments:

Immunotherapy, Adoptive